Physician profile
Maian Ye
NPI 1912198110
$6,587.99
in general payments reported to CMS, 2019-2025
25 companies · $1,319 in 2025
The $1,319 reported for 2025 was more than what 84% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,505 · 2020: $230 · 2021: $18.75 · 2022: $1,046 · 2023: $631 · 2024: $1,839 · 2025: $1,319.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,764 · Education: $24.64.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,763.90 |
| Education | $24.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $885.75 | 2019-2023 | Vemlidy |
| Amgen INC. | $799.55 | 2020-2025 | Tavneos |
| Janssen Pharmaceuticals, INC | $692.72 | 2019-2024 | Xarelto |
| Glaxosmithkline, LLC. | $596.36 | 2023-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Novo Nordisk INC | $517.46 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $433.32 | 2022-2025 | Farxiga, Lokelma |
| Shire North American Group INC | $259.32 | 2019 | |
| Travere Therapeutics, INC. | $252.61 | 2023-2025 | Filspari |
| Boehringer Ingelheim Pharmaceuticals, INC. | $234.38 | 2019-2022 | |
| Stryker Corporation | $173.45 | 2024 | Omnicurve |
| Merck Sharp & Dohme LLC | $163.73 | 2019-2024 | Capvaxive |
| Abbvie INC. | $150.00 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $143.75 | 2021-2022 | |
| Calliditas Therapeutics US INC. | $125.38 | 2024 | |
| Viiv Healthcare Company | $125.00 | 2024 | Apretude |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $125.00 | 2019 | |
| Dynavax Technologies Corporation | $124.99 | 2019 | |
| Horizon Therapeutics Plc | $124.30 | 2023 | Krystexxa |
| Viatris Specialty LLC | $122.39 | 2025 | Yupelri |
| E.R. Squibb & Sons, L.L.C. | $120.00 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $107.70 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $100.64 | 2025 | |
| Lilly USA, LLC | $98.34 | 2024 | Mounjaro |
| Edwards Lifesciences Corporation | $88.18 | 2024 | Sapien 3 Ultra Resilia |
| Mallinckrodt Hospital Products INC. | $23.67 | 2025 | Acthar |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maian Ye listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.